Quantum BioPharma Ltd. Cash Flow Conversion Efficiency
Quantum BioPharma Ltd. cash flow conversion efficiency. Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has a cash flow conversion efficiency ratio of -0.286x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($6.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Quantum BioPharma Ltd. (2015–2025)
Cash flow conversion efficiency of Quantum BioPharma Ltd. from 2015 to 2025. This chart illustrates how Quantum BioPharma Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Quantum BioPharma Ltd. stock price today for real-time trading data and today's change.
Quantum BioPharma Ltd. Cash Flow Conversion Ratio Explained
Quantum BioPharma Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Quantum BioPharma Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quantum BioPharma Ltd. ranked by their cash flow conversion efficiency. Also see QNTM stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alliance Nickel Ltd
AU:AXN
|
-0.021x |
|
DCM Limited
NSE:DCM
|
-0.038x |
|
Honkarakenne Oyj B
HE:HONBS
|
-0.200x |
|
Domo Activos Socimi SA
MC:DOMO
|
-0.014x |
|
4Imprint Group Plc
LSE:FOUR
|
0.566x |
|
Millennium Group International Holdings Limited Ordinary Shares
NASDAQ:MGIH
|
-0.078x |
|
Quartz Mountain Resources Ltd
V:QZM
|
-0.198x |
|
Polwax SA
WAR:PWX
|
-0.416x |
Annual Cash Flow Conversion Efficiency for Quantum BioPharma Ltd. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Quantum BioPharma Ltd. from 2015 to 2025. Review Quantum BioPharma Ltd. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.09 Million | $-8.38 Million | -1.646x | -149.83% |
| 2024-12-31 | $10.44 Million | $-6.88 Million | -0.659x | +21.47% |
| 2023-12-31 | $12.91 Million | $-10.83 Million | -0.839x | +9.59% |
| 2022-12-31 | $30.54 Million | $-28.33 Million | -0.928x | -142.05% |
| 2021-12-31 | $54.13 Million | $-20.75 Million | -0.383x | +27.26% |
| 2020-12-31 | $36.31 Million | $-19.13 Million | -0.527x | -39.39% |
| 2019-12-31 | $36.28 Million | $-13.71 Million | -0.378x | -4.33% |
| 2018-12-31 | $37.47 Million | $-13.58 Million | -0.362x | -2901.19% |
| 2017-12-31 | $9.87 Million | $-119.18K | -0.012x | -102.41% |
| 2016-12-31 | $-54.30K | $-27.24K | 0.502x | +46055.76% |
| 2015-12-31 | $-58.37K | $-63.44 | 0.001x | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more